JNJ
Status-Quo-PlayerJohnson & Johnson
$237.96
-0.20%
as of 13 Apr
Power Core
The moat: JNJ's power derives from being the only company simultaneously entrenched at institutional scale in both pharmaceutical innovation and surgical technology, creating a dual-vertical counterparty position that no competitor can replicate.
Direction of Movement
Lateral With Upward Optionality Pending Key Catalysts
ROC 200
+56.6%
JNJ
Johnson & Johnson
$237.96
-0.20%
as of 13 Apr
DCF Fair Value: $320.57
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, focusing on pharmaceuticals in oncology, immunology, neuroscience, and other therapeutic areas, and MedTech, encompassing medical devices in cardiovascular, orthopaedics, vision care, and electrophysiology. Key products include DARZALEX for oncology, TREMFYA for immunology, and innovative platforms like OMNYPULSE for pulsed-field ablation treatments. Founded in 1887 and headquartered in New Brunswick, New Jersey, the company employs approximately 139,800 people and generates substantial revenue, reaching $94.2 billion in the latest full year with operational growth of 5.3%, driven by a robust pipeline and R&D investments exceeding $32 billion. Johnson & Johnson maintains strong financials, including a dividend yield around 2.1% and consistent payout growth, positioning it as a Dividend King in the healthcare sector. Its diversified portfolio ensures stable cash flows, supporting global distribution through hospitals, physicians, clinics, and partners, while addressing major health challenges across consumer, business, and institutional markets.